Medicare And Medicare Advantage
Customers
0
None disclosed
Suppliers
1
1 disclosed
Top supplier share
28%
of BIOCEPT INC revenue · 3M to 2023-06-30
Top supplier by $
$164.9K
BIOCEPT INC · 3M to 2023-06-30
Latest period
Jun 30, 2023
10-Q filed 2023-08-14
Suppliers 1
Companies that disclose Medicare And Medicare Advantage as a major customer, as a share of their own revenue. 1 active, 0 lapsed.
| Company | % of their revenue | Est. $ from Medicare And Medicare Advantage | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| BIOCEPT INC BIOCEPT INC |
28% | $164.9K | 3M 2023-06-30 | +9.0pp | Active | 10-Q 2023-08-14 |
The Company's third-party payors that represent more than 10% of total net revenues in any period presented during the three and six months ended June 30, 2023 and 2022 were as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 Medicare and Medicare Advantage/CARES Act 28% 12% 21% 36% Blue Cross Blue Shield 17% 16% 15% 16% Kaiser Permanente 1% 23% 3% 16% The Company's third-party payors that represent more than 10% of total accounts receivable at June 30, 2023 and December 31, 2022 were as follows: June 30, December 31, 2023 2022 Blue Cross Blue Shield 28% 23% Recent Accounting PronouncementsIn June 2016, the FASB issued ASU 2016-13, Financial Instruments- Credit Losses, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The Company's third-party payors that represent more than 10% of total net revenues in any period presented during the three months ended March 31, 2023 and 2022 were as follows: For the Three Months Ended March 31, 2023 2022 Medicare and Medicare Advantage/CARES Act 19% 43% Blue Cross Blue Shield 15% 16% Kaiser Permanente 4% 14% The Company's third-party payors that represent more than 10% of total accounts receivable at March 31, 2023 and December 31, 2022 were as follows: March 31, December 31, 2023 2022 Blue Cross Blue Shield 27% 23% Recent Accounting PronouncementsIn June 2016, the FASB issued ASU 2016-13, Financial Instruments- Credit Losses, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types.92 The Company's third-party payors that represent more than 10% of total net revenues in any period presented during the years ended December 31, 2022 and 2021 were as follows: For the year ended December 31, 2022 2021 Medicare and Medicare Advantage/CARES Act 36% 56% Blue Cross Blue Shield 16% 17% Kaiser Permanente 16% 6% The Company's third-party payors that represent more than 10% of total net accounts receivable as of December 31, 2022 and 2021 were as follows: For the year ended December 31, 2022 2021 Medicare and Medicare Advantage/CARES Act 5% 31% Blue Cross Blue Shield 23% 19% The Company operates in one reportable business segment and historically has derived most revenues only from within the United States.Certain components used in the Company’s current or planned products are currently sourced from one supplier, for which alternative suppliers exist but the Company has not validated the product(s) of such alternative supplier(s), and substitutes for these components may not be obtained easily or may require substantial design or manufacturing modifications. The Company's third-party payors that represent more than 10% of total net revenues in any period presented during the three and nine months ended September 30, 2021 and 2022 were as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2021 2022 2021 2022 (As Restated) (As Restated) Medicare and Medicare Advantage/CARES Act 62% 15% 51% 35% Blue Cross Blue Shield 10% 0% 21% 15% Kaiser Permanente 0% 23% 0% 16% The Company's third-party payors that represent more than 10% of total accounts receivable at December 31, 2021 and September 30, 2022 were as follows: December 31, September 30, 2021 2022 (As Restated) Medicare and Medicare Advantage/CARES Act 31% 7% Blue Cross Blue Shield 19% 22% Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments- Credit Losses, which requires the measurement of expected credit losses for financial instruments carried at amortized cost, such as accounts receivable, held at the reporting date based on historical experience, current conditions and reasonable forecasts. Medicare and Medicare Advantage/CARES Act 57 % 12 % 44 % 32 % Medicare and Medicare Advantage/CARES Act 35 % 43 % Medicare and Medicare Advantage/CARES Act 51 % 56 % Medicare and Medicare Advantage/CARES Act 32 % 62 % 32 % 51 % Medicare and Medicare Advantage/CARES Act 30 % 57 % 34 % 44 % Medicare and Medicare Advantage/CARES Act 37 % 35 % Medicare and Medicare Advantage/CARES Act 38 % 51 % Medicare and Medicare Advantage 32 % 32 % 40 % 32 % Medicare and Medicare Advantage 17 % 17 % Medicare and Medicare Advantage 40 % 32 % 39 % 40 % | ||||||
Alerts are coming
Get an email when Medicare And Medicare Advantage's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.